Published in Medicine (Baltimore) on July 01, 1980
How I treat POEMS syndrome. Blood (2012) 1.71
The clinical spectrum of Castleman's disease. Am J Hematol (2012) 1.41
POEMS syndrome complicated by extensive arterial thromboses. Clin Rheumatol (2007) 1.11
Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood (2011) 0.95
Extensive demyelinating changes in the peripheral nerves of Crow-Fukase syndrome: a pathological study of one autopsied case. Acta Neuropathol (1992) 0.94
UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol (2004) 0.93
Serial renal biopsy findings in a case of POEMS syndrome with recurrent acute renal failure. Clin Exp Nephrol (2011) 0.92
Case of POEMS syndrome associated with bilateral macular detachment resolved by autologous peripheral blood stem cell transplantation. Jpn J Ophthalmol (2007) 0.91
An unusual presentation of Castleman's disease:a case report. BMC Infect Dis (2003) 0.90
POEMS Syndrome: A Report of 14 Cases and Review of the Literature. ISRN Gastroenterol (2012) 0.87
POEMS syndrome - a unique presentation of a rare paraneoplastic syndrome. BMJ Case Rep (2010) 0.87
Computed tomography assessment of bone lesions in patients with POEMS syndrome. Eur Radiol (2014) 0.85
Paraproteinemic Neuropathy. Curr Treat Options Neurol (2001) 0.82
Stabilisation of a severe case of P.O.E.M.S. syndrome after tamoxifen administration. J Neurol Neurosurg Psychiatry (1989) 0.82
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open (2015) 0.82
A case of IgD myeloma presenting as diffuse osteosclerosis. J Clin Pathol (1988) 0.81
Pseudotumour cerebri in a patient with Castleman's disease. Postgrad Med J (1988) 0.80
The role of radiotherapy in the management of POEMS syndrome. Radiat Oncol (2014) 0.80
A case of Takayasu arteritis complicated with glomerulonephropathy mimicking membranoproliferative glomerulonephritis: a case report and review of the literature. Rheumatol Int (2006) 0.79
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, multiple myeloma and skin changes) with cranial vault plasmocytoma and the role of surgery in its management: a case report. J Med Case Rep (2013) 0.78
Angiofollicular lymph node hyperplasia with amyloidosis. Postgrad Med J (1989) 0.78
Improvement in the POEMS syndrome after administration of tamoxifen. J Neurol Neurosurg Psychiatry (1992) 0.77
Papilloedema and hypertrichosis: the varied and harried manifestations of POEMS syndrome. BMJ Case Rep (2009) 0.76
A case of POEMS syndrome associated with essential thrombocythaemia and dermal mastocytosis. Postgrad Med J (1990) 0.76
The Japanese plasma cell dyscrasia syndrome: case report and theory of pathogenesis. Postgrad Med J (1982) 0.76
Young patient with arterial thrombosis and skin changes as the onset manifestations: POEMS syndrome. Oncotarget (2016) 0.75
Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant (2014) 0.75
Complete heart block in a patient with POEMS syndrome: A case report. ARYA Atheroscler (2014) 0.75
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) treated with autologous hematopoietic stem cell transplantation: a case report and literature review. Am J Case Rep (2015) 0.75
Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS syndrome): a paraneoplastic syndrome. Oxf Med Case Reports (2015) 0.75
Syndrome of plasma cell dyscrasia, polyneuropathy, and diabetes mellitus. West J Med (1990) 0.75
Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. BMJ Open (2015) 0.75
POEMS syndrome with renal plasmacytoma and classic polyarteritis nodosa: a case report. NDT Plus (2011) 0.75
An Unfortunate Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Change (POEMS). Cureus (2017) 0.75
Portal hypertension as the initial manifestation of POEMS syndrome: a case report. BMC Hematol (2017) 0.75
Volumetric modulated arc radiotherapy for limited osteosclerotic myeloma. World J Radiol (2013) 0.75
T-cell lymphoma with POEMS syndrome. Oncol Lett (2014) 0.75
Syndrome of polyneuropathy, skin hyperpigmentation, oedema and hepatosplenomegaly. J Neurol Neurosurg Psychiatry (1983) 0.75
The first case of POEMS syndrome with synchronous breast cancer: What are the associated diagnostic challenges? Clin Case Rep (2016) 0.75
POEMS syndrome and Waldenström's macroglobulinaemia. J Clin Pathol (1996) 0.75
POEMS syndrome with vascular transformation of the lymph node sinuses: A case report. Oncol Lett (2015) 0.75
Clinical spectrum of Castleman disease-associated neuropathy. Neurology (2016) 0.75
Anaesthetic management of Crow-Fukase syndrome. BMJ Case Rep (2010) 0.75
An Occult Malignancy Behind a Demyelinating Disease: POEMS Syndrome. J Investig Med High Impact Case Rep (2016) 0.75
Cutaneous Manifestations in POEMS Syndrome: Case Report and Review. Case Rep Dermatol (2015) 0.75
Peripheral neuropathy associated with dysproteinaemia, skin changes, and endocrinopathy. Br Med J (Clin Res Ed) (1986) 0.75
Intravitreal Bevacizumab for the Treatment of Optic Disc Edema in a Patient with POEMS Syndrome. Korean J Ophthalmol (2015) 0.75
Long-Term Therapy with Lenalidomide in a Patient with POEMS Syndrome. Eur J Case Rep Intern Med (2015) 0.75
POEMS Syndrome Presentation with an Abscess within the Plasmacytoma-A Rare Case Report. ISRN Hematol (2011) 0.75
Correlation between serum level of vascular endothelial growth factor and subfoveal choroidal thickness in patients with POEMS syndrome. Graefes Arch Clin Exp Ophthalmol (2014) 0.75
Osteolytic-variant POEMS syndrome: an uncommon presentation of "osteosclerotic" myeloma. Skeletal Radiol (2017) 0.75
Portal hypertension and refractory ascites associated with multicentric Castleman's disease. Dig Dis Sci (2000) 0.75
POEMS syndrome with a giant pancreas cyst. Neurol Sci (2011) 0.75
Autoimmune findings resembling connective tissue disease in a patient with Castleman's disease. Clin Rheumatol (1997) 0.75
Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol (1999) 6.18
The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol (1973) 5.64
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum (1990) 5.09
Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn (2010) 4.48
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (2000) 4.18
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
C-kinase phosphorylates the epidermal growth factor receptor and reduces its epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem (1984) 3.88
How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum (1990) 3.78
Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature (1987) 3.75
On the mechanism of action of adrenocorticotropic hormone: the binding of cyclic-3',5'-adenosine monophosphate to an adrenal cortical protein. Proc Natl Acad Sci U S A (1969) 3.50
Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science (1996) 3.20
Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell (1989) 3.12
A cyclic-3',5'-adenosine monophosphate dependent protein kinase from the adrenal cortex: comparison with a cyclic AMP binding protein. Biochem Biophys Res Commun (1970) 2.98
Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science (1990) 2.92
Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A (1997) 2.80
Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature (1981) 2.75
Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science (1984) 2.75
Inhibition of the receptor-binding function of clathrin adaptor protein AP-2 by dominant-negative mutant mu2 subunit and its effects on endocytosis. EMBO J (1999) 2.60
Unusual synovial fluid findings in Reiter's syndrome. Ann Intern Med (1967) 2.47
Apoptosis in rheumatoid arthritis synovium. J Clin Invest (1995) 2.39
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med (1996) 2.35
Breakdown products of C 3 in human synovial fluids. J Clin Invest (1969) 2.31
Protein kinase C phosphorylation at Thr 654 of the unoccupied EGF receptor and EGF binding regulate functional receptor loss by independent mechanisms. Cell (1986) 2.31
Nuclear LIM interactor, a rhombotin and LIM homeodomain interacting protein, is expressed early in neuronal development. Proc Natl Acad Sci U S A (1996) 2.29
Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest (1976) 2.20
Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest (1989) 2.18
The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J Biol Chem (1991) 2.15
Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J Biol Chem (1990) 2.13
Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol (1992) 2.08
Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies. Cell (1988) 2.08
The nuclear LIM domain interactor NLI mediates homo- and heterodimerization of LIM domain transcription factors. J Biol Chem (1998) 2.07
RGS-PX1, a GAP for GalphaS and sorting nexin in vesicular trafficking. Science (2001) 2.05
Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum (1987) 2.04
Functional analysis of the nuclear LIM domain interactor NLI. Mol Cell Biol (1997) 2.04
Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today (2000) 2.03
Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem (1999) 2.03
Rabbit anaphylactic antibody. J Exp Med (1966) 2.01
The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol (2000) 2.00
Cloning, tissue distribution, genomic organization, and functional characterization of NBC3, a new member of the sodium bicarbonate cotransporter family. J Biol Chem (1999) 1.92
Protein-protein interaction of zinc finger LIM domains with protein kinase C. J Biol Chem (1996) 1.90
Reactions of aggregated mercaptoethanol treated gamma globulin with rheumatoid factor--precipitin and complement fixation studies. Arthritis Rheum (1968) 1.88
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation (2001) 1.83
Molecular cloning, chromosomal localization, tissue distribution, and functional expression of the human pancreatic sodium bicarbonate cotransporter. J Biol Chem (1998) 1.83
On the mechanism of action of ACTH. Recent Prog Horm Res (1971) 1.81
Immunoaffinity purification of the epidermal growth factor receptor. Stoichiometry of binding and kinetics of self-phosphorylation. J Biol Chem (1984) 1.80
Self-phosphorylation enhances the protein-tyrosine kinase activity of the epidermal growth factor receptor. J Biol Chem (1985) 1.80
Report of the United States cooperative study of extracorporeal shock wave lithotripsy. J Urol (1986) 1.74
Methods for injury surveillance in international cricket. J Sci Med Sport (2005) 1.69
A genetic linkage map of the baboon (Papio hamadryas) genome based on human microsatellite polymorphisms. Genomics (2000) 1.66
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol (1996) 1.65
Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest (1996) 1.65
Role of the receptor in the mechanism of action of adenosine 3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A (1971) 1.64
Rheumatoid synovitis. An extravascular immune complex disease. Arthritis Rheum (1974) 1.59
Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem (1984) 1.55
Control of bovine adrenal cortical cell proliferation by fibroblast growth factor. Lack of effect of epidermal growth factor. Endocrinology (1977) 1.53
Epstein-Barr virus. Its relationship to the pathogenesis of rheumatoid arthritis. Arthritis Rheum (1981) 1.53
Extracorporeal shock wave lithotripsy: the Methodist Hospital of Indiana experience. J Urol (1986) 1.53
Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor. Proc Natl Acad Sci U S A (1993) 1.53
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum (1997) 1.52
Nucleotide regulation of a eukaryotic protein synthesis initiation complex;. Biochim Biophys Acta (1975) 1.52
Endocytosis and mitogenic signaling. Curr Opin Cell Biol (1999) 1.52
Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol (1991) 1.52
Endocytosis and lysosomal targeting of epidermal growth factor receptors are mediated by distinct sequences independent of the tyrosine kinase domain. J Biol Chem (1995) 1.52
Antigen induced histamine release from platelets of rabbits producing homologous PCA antibody. Proc Soc Exp Biol Med (1966) 1.51
Altered epidermal growth factor (EGF)-stimulated protein kinase activity in variant A431 cells with altered growth responses to EGF. Proc Natl Acad Sci U S A (1982) 1.47
LIM domain recognition of a tyrosine-containing tight turn. J Biol Chem (1994) 1.47
Identification of immunostimulatory dendritic cells in the synovial effusions of patients with rheumatoid arthritis. J Clin Invest (1985) 1.47
Production of an epidermal growth factor receptor-related protein. Science (1984) 1.46
Alteration of epidermal growth factor receptor activity by mutation of its primary carboxyl-terminal site of tyrosine self-phosphorylation. J Biol Chem (1988) 1.46
Effect of physiological mechanical perturbations on intact human myocardial repolarization. Cardiovasc Res (2000) 1.45
Impaired regulation of Epstein-Barr virus-induced lymphocyte proliferation in rheumatoid arthritis is due to a T cell defect. J Immunol (1981) 1.44
Interaction between the epidermal growth factor receptor and phosphoinositide kinases. J Biol Chem (1991) 1.40
Hyperglycemia and hyperosmolality complicating peritoneal dialysis. Ann Intern Med (1967) 1.40
The painful shoulder: Part I. Extrinsic disorders. Am Fam Physician (1991) 1.40
Variability of acoustic segment durations after prolonged-speech treatment for stuttering. J Speech Hear Res (1992) 1.38
Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum (2002) 1.38
Methods for injury surveillance in international cricket. Br J Sports Med (2005) 1.38
Quantitative phagocytosis by neutrophils. I. A new method with immune complexes. J Immunol (1973) 1.36
Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus. Clin Exp Immunol (1972) 1.36
p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis Rheum (1999) 1.35
Association of epidermal growth factor receptors with coated pit adaptins via a tyrosine phosphorylation-regulated mechanism. J Biol Chem (1995) 1.34
Altered regulation of Epstein-Barr virus induced lymphoblast proliferation in rheumatoid arthritis lymphoid cells. Arthritis Rheum (1980) 1.31
Chip and apterous physically interact to form a functional complex during Drosophila development. Mol Cell (1999) 1.30
Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest (2001) 1.30
Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH. J Biol Chem (1997) 1.30
A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C. Mol Cell Biol (1992) 1.29
Ligand-induced endocytosis of epidermal growth factor receptors that are defective in binding adaptor proteins. Proc Natl Acad Sci U S A (1995) 1.28
Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum (1994) 1.26
Rabbit homocytotropic antibody. A unique rabbit immunoglobulin analogous to human IgE. J Exp Med (1969) 1.26
Pigmented villonodular synovitis: MRI characteristics. Skeletal Radiol (1995) 1.26